On the stock market since 2015, it operates in the world of health and science. It has 682 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 11% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 41% a year on average.
The company sells $508.8M a year; the problem isn’t sales — it’s costs running above that number.
There is $615.5M in the vault; even if every debt were paid off, $146.4M would remain.
A loss of $67.1M against $508.8M in annual sales.
The stock trades 13% above the average analyst price target.
On our five-subject report card, BPMC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BPMC has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.